Please login to the form below

Not currently logged in
Email:
Password:

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

Takeda

Takeda, Japan’s largest pharmaceutical company by sales, has announced that it’s considering a possible takeover deal for Shire, a biopharma focused on rare diseases.

The news sparked a 25% surge in Shire’s shares during yesterday morning’s trading however according to Takeda, the consideration of such an offer is at a ‘preliminary’ and exploratory’ stage, with no actual approach made to the board of Shire.

In a press release announced earlier today, Takeda said a “potential transaction with Shire presents an opportunity to strengthen the company’s core therapeutic areas of oncology, gastrointestinal and neuroscience”.

It also added that the deal could build on Takeda’s “current strong momentum”, and could create a “truly global, value-based Japanese biopharmaceutical leader”.

Takeda, which has until 25 April to make a formal offer, isn’t the only company that has seen potential with Shire, as it was recently tipped as the next big pharma takeover after AbbVie’s failed takeover bid in 2014.

That particular deal, which saw AbbVie offer $55bn for the biopharma, came to a halt after the US introduced new measures to discourage tax inversion deals.

Article by
Gemma Jones

29th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics